SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the enrollment of the first patient in the Company’s Phase 2b efficacy study of KAI-9803, KAI’s proprietary, first-in-class inhibitor of the delta protein kinase C pathway (delta PKC). The Phase 2b trial (PROTECTION AMI) is designed to assess the effect of KAI-9803 on reducing myocardial injury in patients with ST segment elevation myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention (PCI). KAI-9803 is conducting the Phase 2b trial which is being funded by Bristol-Myers Squibb Company (NYSE: BMY) under a global development and commercialization collaboration.
